BioSpace· Annalee Armstrong·· 7 hours agoPickScore65
Alphabet’s GV is one of biotech’s most influential corporate investors
In brief
Alphabet's GV has participated in 20 biotech deals worth a cumulative $5.23 billion since the beginning of 2025, making it the largest corporate venture spender in biotech according to PitchBook data.
Why it matters
PitchBook data compares GV's cumulative spend and deal count with major pharma corporate venture arms, quantifying capital allocation in biotech.
Source: BioSpace · biospace.com